The present invention provides pegylated IFN-β variants and compositions for the prophylaxis or treatment of hyperproliferative diseases, inflammatory diseases, autoimmune diseases or viral infectious diseases comprising the same as an active ingredient. The pegylated IFN- [beta] mutant of the present invention has excellent anti-viral efficacy, immunoregulatory and anti-cell growth efficacy due to its excellent pharmacokinetic properties as compared with native IFN- [beta] and non-pegylated IFN- And can be usefully used for diseases. The present invention exhibits excellent pharmacological activity at the time of administration, and the blood half-life is significantly higher than that of conventional interferon preparations.
展开▼
